Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Apr 09, 2024
Triple-negative breast cancer (TNBC) accounts for 15–20% of incident breast cancers and is the only breast cancer (BC) subtype lacking targeted treatments. It is a biologically aggressive tumor characterized by moderate/high grade and highly proliferative cancer cells, which, together with limited treatment options, leads to the poorest prognosis among breast cancer subtypes.
BRCA gene mutations, particularly BRCA1 mutations, are strongly correlated with an increased risk of developing TNBC. As per DelveInsight’s analysis, out of all gene mutation specific TNBC cases in US in 2023, around 5,000 were BRAC gene mutation cases.
Unlike other forms of breast cancer, TNBC does not respond to treatment with hormonal or HER2-targeted treatment. For a long time, systemic chemotherapy remained the mainstay treatment for metastatic TNBC. But the recent approval of various immune checkpoint inhibitors (like pembrolizumab) and targeted therapies (like olaparib and talazoparib) has led to a dynamic shift in the treatment landscape, with their increased usage across various lines of therapy, leading to significant improvement in treatment outcomes and patient prognosis.
Article in PDF
The latest findings from the PARTNER Trial (NCT03150576), unveiled at AACR 2024, evaluated the efficacy of LYNPARZA (olaparib) alongside carboplatin and paclitaxel in a neoadjuvant setting for BRCA Wild-Type TNBC. Disappointingly, the trial did not reveal improved outcomes compared to chemotherapy alone.
The results, drawn from a cohort of 281 patients on olaparib and 269 on chemotherapy alone, showed no statistically significant difference in pathological complete response rates (pCR), the primary endpoint (∆ -1.3%; 95% CI, -9.7% to 7.0%; P = .753). Surgical intervention rates stood at 51.1% versus 52.4%, respectively. Secondary endpoints, including 36-month event-free survival (EFS) and overall survival (OS) rates, mirrored marginal variations (80% vs. 79% and 90% vs. 87%, respectively).
Despite these setbacks, the gap schedule regimen provides a biologically relevant concept that should be considered when testing future PARP inhibitor combinations.
For more information, refer DelveInsight’s report:
Triple Negative Breast Cancer (TNBC) – Market Insight, Epidemiology And Market Forecast – 2032
Article in PDF
